We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
- Authors
Kosmidis, P; Mylonakis, N; Skarlos, D; Samantas, E; Dimopoulos, M; Papadimitriou, C; Kalophonos, C; Pavlidis, N; Nikolaidis, C; Papaconstantinou, C; Fountzilas, G
- Abstract
The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present prospective study was to evaluate the dose response relationship of paclitaxel.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Vol 11, Issue 7, p799
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1023/a:1008389402580